ACET Adicet Bio, Inc.
Healthcare · Market cap: $26.0M
–
Bought and sold by quarter, last 5 years
Open-market purchases and sales by this company's insiders, in dollars, last 5 years
| Quarter | Bought | Sold |
|---|---|---|
| 2022-Q1 | $0 | $289.6K |
| 2022-Q2 | $0 | $327.6K |
| 2022-Q3 | $0 | $1.6M |
| 2022-Q4 | $0 | $2.1M |
| 2023-Q1 | $0 | $117.8K |
| 2023-Q2 | $3.7M | $0 |
| 2023-Q3 | $7.8K | $15.3K |
| 2023-Q4 | $7.3K | $0 |
| 2024-Q1 | $15.0M | $0 |
| 2024-Q2 | $0 | $8.4K |
| 2024-Q3 | $0 | $0 |
| 2024-Q4 | $0 | $0 |
| 2025-Q1 | $0 | $0 |
| 2025-Q2 | $0 | $0 |
| 2025-Q3 | $0 | $0 |
| 2025-Q4 | $5.0M | $0 |
| 2026-Q1 | $1.6M | $0 |
| 2026-Q2 | $0 | $674.8K |
| 2026-Q3 | $0 | $0 |
| 2026-Q4 | $0 | $0 |
Bought$32.3M12 buy days
Sold$5.2M28 sell days
Net insider flow+$27.1Mnet buying · 5 years
Latest trade2026-04-08ORBIMED ADVISORS LLC
| Date | Side | Insider | Role | Shares | Avg price | Value | Trades |
|---|---|---|---|---|---|---|---|
| 2026-04-08 | Sell | ORBIMED ADVISORS LLC | 10% owner | 72,939 | $6.42 | $468.1K | 2 |
| 2026-04-07 | Sell | ORBIMED ADVISORS LLC | 10% owner | 31,719 | $6.52 | $206.8K | 2 |
| 2026-02-20 | Buy | RA Capital Healthcare Fund LP | 10% owner | 74,751 | $7.27 | $543.4K | 1 |
| 2026-02-19 | Buy | RA Capital Healthcare Fund LP | 10% owner | 74,268 | $7.21 | $535.5K | 1 |
| 2026-02-18 | Buy | RA Capital Healthcare Fund LP | 10% owner | 74,577 | $7.04 | $525.0K | 1 |
| 2025-10-08 | Buy | ORBIMED ADVISORS LLC | 10% owner | 5,000,000 | $1.00 | $5.0M | 2 |
| 2024-06-05 | Sell | Kauffman Michael | Director | 5,900 | $1.43 | $8.4K | 1 |
| 2024-01-25 | Buy | GORDON CARL L | Director | 3,125,000 | $2.40 | $7.5M | 3 |
| 2024-01-25 | Buy | ORBIMED ADVISORS LLC | Director | 3,125,000 | $2.40 | $7.5M | 3 |
| 2023-10-02 | Buy | Schor Chen | CEO | 5,500 | $1.33 | $7.3K | 1 |
| 2023-09-29 | Sell | Schor Chen | CEO | 5,500 | $1.36 | $7.5K | 1 |
| 2023-09-28 | Sell | Schor Chen | CEO | 5,500 | $1.42 | $7.8K | 1 |
| 2023-09-28 | Buy | Schor Chen | CEO | 5,500 | $1.42 | $7.8K | 1 |
| 2023-06-30 | Buy | DUBIN STEVE | Director | 5,000 | $2.40 | $12.0K | 1 |
| 2023-06-27 | Buy | GORDON CARL L | Director | 875,000 | $2.09 | $1.8M | 4 |
| 2023-06-27 | Buy | Chimovits Erez | Director | 875,000 | $2.09 | $1.8M | 4 |
| 2023-02-15 | Sell | Healey Don | Other C-suite | 4,533 | $7.57 | $34.3K | 1 |
| 2023-02-10 | Sell | Healey Don | Other C-suite | 10,467 | $7.98 | $83.5K | 1 |
| 2022-11-10 | Sell | Schor Chen | CEO | 39,955 | $20.30 | $811.2K | 2 |
| 2022-11-10 | Sell | Aftab Blake | Other C-suite | 6,967 | $21.00 | $146.3K | 1 |
| 2022-11-07 | Sell | Schor Chen | CEO | 30,000 | $19.05 | $571.5K | 1 |
| 2022-11-03 | Sell | Schor Chen | CEO | 24,813 | $18.04 | $447.6K | 1 |
| 2022-11-02 | Sell | Schor Chen | CEO | 500 | $18.00 | $9.0K | 1 |
| 2022-10-19 | Sell | Aftab Blake | Other C-suite | 8,067 | $16.27 | $131.3K | 1 |
| 2022-10-12 | Sell | Aftab Blake | Other C-suite | 1,646 | $15.40 | $25.3K | 1 |
| 2022-09-14 | Sell | Schor Chen | CEO | 952 | $18.00 | $17.1K | 1 |
| 2022-09-13 | Sell | CEO | 3,371 | $18.01 | $60.7K | 1 | |
| 2022-09-12 | Sell | CEO | 66,947 | $16.77 | $1.1M | 2 | |
| 2022-09-09 | Sell | CEO | 8,094 | $16.51 | $133.6K | 1 | |
| 2022-08-03 | Sell | Aftab Blake | Other C-suite | 6,968 | $18.00 | $125.4K | 1 |
| 2022-08-01 | Sell | Aftab Blake | Other C-suite | 6,968 | $16.64 | $115.9K | 1 |
| 2022-07-05 | Sell | Aftab Blake | Other C-suite | 1,363 | $14.50 | $19.8K | 1 |
| 2022-04-04 | Sell | Galimi Francesco | Other C-suite | 7,979 | $21.00 | $167.6K | 3 |
| 2022-04-01 | Sell | Galimi Francesco | Other C-suite | 7,621 | $21.00 | $160.0K | 1 |
| 2022-03-09 | Sell | Jakobovits Aya | Director | 2,000 | $14.00 | $28.0K | 1 |
| 2022-02-16 | Sell | Jakobovits Aya | Director | 2,000 | $14.83 | $29.7K | 1 |
| 2022-02-09 | Sell | Jakobovits Aya | Director | 4,000 | $14.03 | $56.1K | 1 |
| 2022-01-05 | Sell | Jakobovits Aya | Director | 4,000 | $16.91 | $67.7K | 2 |
| 2022-01-03 | Sell | Jakobovits Aya | Director | 6,000 | $18.02 | $108.1K | 1 |
| 2021-12-08 | Buy | Sinclair Andrew | Director | 500,000 | $14.00 | $7.0M | 1 |
Who the insiders are, last 5 years
Everyone who bought or sold this company's shares on the open market in the last 5 years, biggest first.
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% owner | $14.3M | $674.8K | 2026-04-08 |
| GORDON CARL L | Director | $9.3M | $0 | 2024-01-25 |
| Sinclair Andrew | Director | $7.0M | $0 | 2021-12-08 |
| Schor Chen | CEO | $15.1K | $3.2M | 2023-10-02 |
| RA Capital Healthcare Fund LP | 10% owner | $1.6M | $0 | 2026-02-20 |
| Aftab Blake | Other C-suite | $0 | $564.0K | 2022-11-10 |
| Galimi Francesco | Other C-suite | $0 | $327.6K | 2022-04-04 |
| Jakobovits Aya | Director | $0 | $289.6K | 2022-03-09 |
| Healey Don | Other C-suite | $0 | $117.8K | 2023-02-15 |
| DUBIN STEVE | Director | $12.0K | $0 | 2023-06-30 |
| Kauffman Michael | Director | $0 | $8.4K | 2024-06-05 |
Past buying clusters
A cluster is a run of purchases by three or more insiders. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.
| Window | Insiders | Total | Score | 21 days vs benchmark | 63 days vs benchmark | 126 days vs benchmark | Status |
|---|---|---|---|---|---|---|---|
| 2023-06-27 → 2023-06-30 | 3 | $3.7M | 57 | -2.3% (+2.1% raw) | -39.7% (-46.1% raw) | -24.9% (-17.3% raw) | closed |
| 2018-01-30 | 3 | $19.5M | 45 | +17.7% (+12.9% raw) | -28.7% (-35.2% raw) | -15.9% (-15.7% raw) | closed |
Yahoo Finance data, delayed, loaded through this server. Informational only; not investment advice.